Fig. 2.

Results of BRAF V600E mutation testing and MLH1 promoter methylation analysis. According to the guidelines of LS screening, 17.2% of patients with the BRAF V600E mutation could be precluded from germline genetic testing, while 45.5% of patients who displayed negative MLH1 promoter methylation were referred for germline genetic testing. The pathogenic variant status of the remaining 37.3% of patients needed to be clarified due to the possibility of coexisting MLH1 promoter methylation and a germline mutation.